Torley said results coming by end of quarter and today's price action suggests either some nervous nellies out there or knowledge of something negative on the horizon. Looking at it from a scientific point of view my guess is that the cellulite trial will be a bust, and I'm not knowledgeable enough to make a guess re: insulin. But I think we just need to keep our eye on the ball. The biggie is pancreatic ca which has a good chance of being successful. And if that works, the applications of the technology to chemotherapy of other tumors are obvious and were mentioned in her recent presentation.
Could be rough. The price action on Friday suggests an imminent downgrade by a brokerage house (the upgrade from BMO clearly didn't do much) and the market will likely be in the tank given the Ukraine situation. Anyone with more than a 10 minute time horizon would do well to simply turn off their computer and stay the course.
...if the pancreatic ca study was not going well why would they be looking at another trial with a different tumor? If the proof of concept is successful the possibilities are endless.
If you want to understand the challenges facing HERO (and why the stock has been under pressure) take the time to listen to yesterday's webcast. It got me out of the stock after holding for 3+ years.
Just trying to be helpful. The worst form of ignorance is not knowing what you don't know. Do some reading, learn about "intent to treat" analysis, and ignore today's news at your own peril. You've been warned. I'm outta here.
When evaluating treatment response the FDA requires an "intent to treat" analysis. This means that all drop outs are considered nonresponders. Today's news is therefore very discouraging.
500 shares @ $16.73 @ 4:46 PM. Last trade $15.93. Volume light.
You can get this information at http://www.nasdaq.com/symbol/halo/after-hours
For all you techies, this is from the 12/30 edition:
Recommendation: Stock is a Buy.
Moving Average Convergence/Divergence (MACD) indicates a Bullish Trend.
Chart pattern indicates a Strong Upward Trend.
Relative Strength is Bullish.
Up/Down volume pattern indicates that the stock is under Accumulation.
The 50 day Moving Average is rising which is Bullish.
The 200 day Moving Average is rising which is Bullish.
Look for Support at 13.02
Stock broke Double Top (Bullish) Point & Figure Chart Formation Last Week
Amgen = Enbrel
Abbott = Humira
Anyway, both are already SQ so I don't understand the relevance to HALO.
From the press release: "Aegis Capital Corp. is acting as sole placement agent for the offering."
This is the same Aegis Capital that recently initiated coverage of ORMP with a price target of $25.
Ladies and gentlemen, you have been scammed.
Agreed, nothing announced as of yet, but the $66M in the bank isn't nearly enough to bring the drug to market, so either they do a secondary to raise some cash or get a partner to finance the trials (unwise, IMO, as they'd have to give up some royalties should the drug succeed).
Usually not, but...try XOMA and AMBI for recent (ie. past 2 weeks) examples of big moves after healthcare conferences. I agree that Torley may have been brought in to sell the company but it certainly is not going to happen by mid-January.